A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-017-4199-3
Abstract: Purpose Combining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 > 15%).MethodsThis randomized, multicenter, international, phase II… read more here.
Keywords: exemestane; ridaforolimus; positive breast; breast cancer ... See more keywords
TCT-92 Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes of the Pooled BIONICS and NIREUS Trials
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.08.1188
Abstract: In the BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis (BIONICS) and the NIREUS trials, the safety and efficacy of the novel ridaforolimus-eluting stent (RES) was evaluated, demonstrating the noninferiority of this stent in comparison… read more here.
Keywords: nireus trials; zotarolimus eluting; ridaforolimus; bionics nireus ... See more keywords